Fulcrum Therapeutics (FULC) Capital Expenditures (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Capital Expenditures of $108000.0 for Q2 2026, up 66.15% year-over-year from $65000.0 in Q2 2025, and up 1250.0% quarter-over-quarter from $8000.0 in Q1 2026.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) Capital Expenditures (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Capital Expenditures for 9 consecutive years, with $108000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Capital Expenditures rose 66.15% year-over-year to $108000.0; the TTM figure through Jun 2026 stood at $365000.0 (up 15.87% YoY), while the FY2025 annual figure was $314000.0, up 12.95% from the prior year.
- Capital Expenditures advanced to $108000.0 in Q2 2026 per FULC's latest filing, from $8000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $847000.0 in Q1 2022 and bottomed at $8000.0 in Q1 2026.
- Historically, Capital Expenditures has averaged $198687.5 across 5 years, with a median of $112000.0 in 2022.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 223.28% — and 2024, when it slumped 83.63%.
- Fulcrum Therapeutics' Capital Expenditures stood at $116000.0 in 2022, then sank by 33.62% to $77000.0 in 2023, then climbed by 27.27% to $98000.0 in 2024, then surged by 58.16% to $155000.0 in 2025, then sank by 30.32% to $108000.0 in 2026.
- Business Quant data shows FULC's Capital Expenditures at $108000.0 in Q2 2026, $8000.0 in Q1 2026, and $155000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - | 108,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 108,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 155,000.00 |
| Sep 30, 2025 | 94,000.00 |
| Jun 30, 2025 | 65,000.00 |
| Dec 31, 2024 | 98,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Dec 31, 2023 | 77,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Jun 30, 2023 | 195,000.00 |
| Mar 31, 2023 | 171,000.00 |
| Dec 31, 2022 | 116,000.00 |
| Sep 30, 2022 | 283,000.00 |
| Jun 30, 2022 | 717,000.00 |
| Mar 31, 2022 | 847,000.00 |
| Dec 31, 2021 | 519,000.00 |
| Sep 30, 2021 | 367,000.00 |
| Jun 30, 2021 | 565,000.00 |
| Mar 31, 2021 | 262,000.00 |